Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Moving Forward: Recent Developments for the Ferret Biomedical Research Model.

Albrecht RA, Liu WC, Sant AJ, Tompkins SM, Pekosz A, Meliopoulos V, Cherry S, Thomas PG, Schultz-Cherry S.

MBio. 2018 Jul 17;9(4). pii: e01113-18. doi: 10.1128/mBio.01113-18. Review.

2.

Broadly Reactive Human Monoclonal Antibodies Elicited following Pandemic H1N1 Influenza Virus Exposure Protect Mice against Highly Pathogenic H5N1 Challenge.

Nachbagauer R, Shore D, Yang H, Johnson SK, Gabbard JD, Tompkins SM, Wrammert J, Wilson PC, Stevens J, Ahmed R, Krammer F, Ellebedy AH.

J Virol. 2018 Jul 31;92(16). pii: e00949-18. doi: 10.1128/JVI.00949-18. Print 2018 Aug 15.

3.

Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses.

Yoon JJ, Toots M, Lee S, Lee ME, Ludeke B, Luczo JM, Ganti K, Cox RM, Sticher ZM, Edpuganti V, Mitchell DG, Lockwood MA, Kolykhalov AA, Greninger AL, Moore ML, Painter GR, Lowen AC, Tompkins SM, Fearns R, Natchus MG, Plemper RK.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00766-18. doi: 10.1128/AAC.00766-18. Print 2018 Aug.

4.

Developing a platform system for gene delivery: amplifying virus-like particles (AVLP) as an influenza vaccine.

Wei H, Chen Z, Elson A, Li Z, Abraham M, Phan S, Kristhnamurthy S, McCray PB Jr, Andrews S, Stice S, Sakamoto K, Jones C, Tompkins SM, He B.

NPJ Vaccines. 2017 Nov 20;2:32. doi: 10.1038/s41541-017-0031-7. eCollection 2017.

5.

Influenza Pathogenesis in Genetically Defined Resistant and Susceptible Murine Strains

.

Samet SJ, Tompkins SM.

Yale J Biol Med. 2017 Sep 25;90(3):471-479. eCollection 2017 Sep. Review.

6.

Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.

Mooney AJ, Gabbard JD, Li Z, Dlugolenski DA, Johnson SK, Tripp RA, He B, Tompkins SM.

J Virol. 2017 Nov 14;91(23). pii: e01579-17. doi: 10.1128/JVI.01579-17. Print 2017 Dec 1.

7.

Potential for Low-Pathogenic Avian H7 Influenza A Viruses To Replicate and Cause Disease in a Mammalian Model.

Zanin M, Koçer ZA, Poulson RL, Gabbard JD, Howerth EW, Jones CA, Friedman K, Seiler J, Danner A, Kercher L, McBride R, Paulson JC, Wentworth DE, Krauss S, Tompkins SM, Stallknecht DE, Webster RG.

J Virol. 2017 Jan 18;91(3). pii: e01934-16. doi: 10.1128/JVI.01934-16. Print 2017 Feb 1.

8.

Comparison of Microchip Transponder and Noncontact Infrared Thermometry with Rectal Thermometry in Domestic Swine (Sus scrofa domestica).

Jara AL, Hanson JM, Gabbard JD, Johnson SK, Register ET, He B, Tompkins SM.

J Am Assoc Lab Anim Sci. 2016;55(5):588-93.

9.

Coated protein nanoclusters from influenza H7N9 HA are highly immunogenic and induce robust protective immunity.

Wang L, Chang TZ, He Y, Kim JR, Wang S, Mohan T, Berman Z, Tompkins SM, Tripp RA, Compans RW, Champion JA, Wang BZ.

Nanomedicine. 2017 Jan;13(1):253-262. doi: 10.1016/j.nano.2016.09.001. Epub 2016 Sep 10.

10.

Environmental Stability of Swine and Human Pandemic Influenza Viruses in Water under Variable Conditions of Temperature, Salinity, and pH.

Poulson RL, Tompkins SM, Berghaus RD, Brown JD, Stallknecht DE.

Appl Environ Microbiol. 2016 Jun 13;82(13):3721-3726. doi: 10.1128/AEM.00133-16. Print 2016 Jul 1.

11.

Erratum to: Serial passage in ducks of a low-pathogenic avian influenza virus isolated from a chicken reveals a high mutation rate in the hemagglutinin that is likely due to selection in the host.

Ridenour C, Williams SM, Jones L, Tompkins SM, Tripp RA, Mundt E.

Arch Virol. 2016 May;161(5):1423. doi: 10.1007/s00705-016-2837-4. No abstract available.

PMID:
27038824
12.

Genome-wide siRNA Screening at Biosafety Level 4 Reveals a Crucial Role for Fibrillarin in Henipavirus Infection.

Deffrasnes C, Marsh GA, Foo CH, Rootes CL, Gould CM, Grusovin J, Monaghan P, Lo MK, Tompkins SM, Adams TE, Lowenthal JW, Simpson KJ, Stewart CR, Bean AG, Wang LF.

PLoS Pathog. 2016 Mar 24;12(3):e1005478. doi: 10.1371/journal.ppat.1005478. eCollection 2016 Mar.

13.

Engineering Enhanced Vaccine Cell Lines To Eradicate Vaccine-Preventable Diseases: the Polio End Game.

van der Sanden SM, Wu W, Dybdahl-Sissoko N, Weldon WC, Brooks P, O'Donnell J, Jones LP, Brown C, Tompkins SM, Oberste MS, Karpilow J, Tripp RA.

J Virol. 2015 Nov 18;90(4):1694-704. doi: 10.1128/JVI.01464-15. Print 2016 Feb 15.

14.

Detection of neuraminidase stalk motifs associated with enhanced N1 subtype influenza A virulence via Raman spectroscopy.

Choi J, Martin SJ, Tripp RA, Tompkins SM, Dluhy RA.

Analyst. 2015 Nov 21;140(22):7748-60. doi: 10.1039/c5an00977d.

15.

Serial passage in ducks of a low-pathogenic avian influenza virus isolated from a chicken reveals a high mutation rate in the hemagglutinin that is likely due to selection in the host.

Ridenour C, Williams SM, Jones L, Tompkins SM, Tripp RA, Mundt E.

Arch Virol. 2015 Oct;160(10):2455-70. doi: 10.1007/s00705-015-2504-1. Epub 2015 Jul 16. Erratum in: Arch Virol. 2016 May;161(5):1423.

PMID:
26179620
16.

Efficacy of a parainfluenza virus 5 (PIV5)-based H7N9 vaccine in mice and guinea pigs: antibody titer towards HA was not a good indicator for protection.

Li Z, Gabbard JD, Johnson S, Dlugolenski D, Phan S, Tompkins SM, He B.

PLoS One. 2015 Mar 24;10(3):e0120355. doi: 10.1371/journal.pone.0120355. eCollection 2015.

17.

Swine Influenza Virus PA and Neuraminidase Gene Reassortment into Human H1N1 Influenza Virus Is Associated with an Altered Pathogenic Phenotype Linked to Increased MIP-2 Expression.

Dlugolenski D, Jones L, Howerth E, Wentworth D, Tompkins SM, Tripp RA.

J Virol. 2015 May;89(10):5651-67. doi: 10.1128/JVI.00087-15. Epub 2015 Mar 11.

18.

Interferon Lambda Upregulates IDO1 Expression in Respiratory Epithelial Cells After Influenza Virus Infection.

Fox JM, Crabtree JM, Sage LK, Tompkins SM, Tripp RA.

J Interferon Cytokine Res. 2015 Jul;35(7):554-62. doi: 10.1089/jir.2014.0052. Epub 2015 Mar 10.

19.

Memory T cells generated by prior exposure to influenza cross react with the novel H7N9 influenza virus and confer protective heterosubtypic immunity.

McMaster SR, Gabbard JD, Koutsonanos DG, Compans RW, Tripp RA, Tompkins SM, Kohlmeier JE.

PLoS One. 2015 Feb 11;10(2):e0115725. doi: 10.1371/journal.pone.0115725. eCollection 2015.

20.

In ovo and in vitro susceptibility of American alligators (Alligator mississippiensis) to avian influenza virus infection.

Temple BL, Finger JW Jr, Jones CA, Gabbard JD, Jelesijevic T, Uhl EW, Hogan RJ, Glenn TC, Tompkins SM.

J Wildl Dis. 2015 Jan;51(1):187-98. doi: 10.7589/2013-12-321.

PMID:
25380354
21.

H7N9 influenza A virus in turkeys in Minnesota.

Lebarbenchon C, Pedersen JC, Sreevatsan S, Ramey AM, Dugan VG, Halpin RA, Ferro PJ, Lupiani B, Enomoto S, Poulson RL, Smeltzer M, Cardona CJ, Tompkins SM, Wentworth DE, Stallknecht DE, Brown JD.

J Gen Virol. 2015 Feb;96(Pt 2):269-76. doi: 10.1099/vir.0.067504-0. Epub 2014 Oct 28.

22.

Polymerase discordance in novel swine influenza H3N2v constellations is tolerated in swine but not human respiratory epithelial cells.

Powell JD, Dlugolenski D, Nagy T, Gabbard J, Lee C, Tompkins SM, Tripp RA.

PLoS One. 2014 Oct 16;9(10):e110264. doi: 10.1371/journal.pone.0110264. eCollection 2014.

23.

Influenza Research & Development - GTCBio's Third Annual Conference (July 9-11 - Boston, Massachusetts, USA, 2014).

Tompkins SM.

Drugs Today (Barc). 2014 Aug;50(8):599-605. doi: 10.1358/dot.2014.50.7.2211414.

PMID:
25187909
24.

Virus-vectored influenza virus vaccines.

Tripp RA, Tompkins SM.

Viruses. 2014 Aug 7;6(8):3055-79. doi: 10.3390/v6083055. Review.

25.

Verdinexor, a novel selective inhibitor of nuclear export, reduces influenza a virus replication in vitro and in vivo.

Perwitasari O, Johnson S, Yan X, Howerth E, Shacham S, Landesman Y, Baloglu E, McCauley D, Tamir S, Tompkins SM, Tripp RA.

J Virol. 2014 Sep 1;88(17):10228-43. doi: 10.1128/JVI.01774-14. Epub 2014 Jun 25.

26.

Identification of virulence determinants in influenza viruses.

Negri P, Choi JY, Jones C, Tompkins SM, Tripp RA, Dluhy RA.

Anal Chem. 2014 Jul 15;86(14):6911-7. doi: 10.1021/ac500659f. Epub 2014 Jun 27.

27.

Drug analog inhibition of indoleamine 2,3-dioxygenase (IDO) activity modifies pattern recognition receptor expression and proinflammatory cytokine responses early during influenza virus infection.

Fox JM, Sage LK, Poore S, Johnson S, Tompkins SM, Tripp RA.

J Leukoc Biol. 2014 Sep;96(3):447-52. doi: 10.1189/jlb.3AB0114-046RR. Epub 2014 May 5.

28.

Indoleamine 2,3-dioxygenase (IDO) activity during the primary immune response to influenza infection modifies the memory T cell response to influenza challenge.

Sage LK, Fox JM, Mellor AL, Tompkins SM, Tripp RA.

Viral Immunol. 2014 Apr;27(3):112-23. doi: 10.1089/vim.2013.0105. Epub 2014 Apr 4.

29.

Multiplexed screening of natural humoral immunity identifies antibodies at fine specificity for complex and dynamic viral targets.

McCutcheon KM, Gray J, Chen NY, Liu K, Park M, Ellsworth S, Tripp RA, Tompkins SM, Johnson SK, Samet S, Pereira L, Kauvar LM.

MAbs. 2014 Mar-Apr;6(2):460-73. doi: 10.4161/mabs.27760. Epub 2014 Jan 8.

30.

siRNA Genome Screening Approaches to Therapeutic Drug Repositioning.

Perwitasari O, Bakre A, Tompkins SM, Tripp RA.

Pharmaceuticals (Basel). 2013 Jan 28;6(2):124-60. doi: 10.3390/ph6020124.

31.

Novel H7N9 influenza virus shows low infectious dose, high growth rate, and efficient contact transmission in the guinea pig model.

Gabbard JD, Dlugolenski D, Van Riel D, Marshall N, Galloway SE, Howerth EW, Campbell PJ, Jones C, Johnson S, Byrd-Leotis L, Steinhauer DA, Kuiken T, Tompkins SM, Tripp R, Lowen AC, Steel J.

J Virol. 2014 Feb;88(3):1502-12. doi: 10.1128/JVI.02959-13. Epub 2013 Nov 13.

32.

Targeting cell division cycle 25 homolog B to regulate influenza virus replication.

Perwitasari O, Torrecilhas AC, Yan X, Johnson S, White C, Tompkins SM, Tripp RA.

J Virol. 2013 Dec;87(24):13775-84. doi: 10.1128/JVI.01509-13. Epub 2013 Oct 9.

33.

Gain-of-function experiments on H7N9.

Fouchier RA, Kawaoka Y, Cardona C, Compans RW, García-Sastre A, Govorkova EA, Guan Y, Herfst S, Orenstein WA, Peiris JS, Perez DR, Richt JA, Russell C, Schultz-Cherry SL, Smith DJ, Steel J, Tompkins SM, Topham DJ, Treanor JJ, Tripp RA, Webby RJ, Webster RG.

Science. 2013 Aug 9;341(6146):612-3. doi: 10.1126/science.341.6146.612. No abstract available.

PMID:
23929965
34.

Avian flu: Gain-of-function experiments on H7N9.

Fouchier RA, Kawaoka Y, Cardona C, Compans RW, Fouchier RA, García-Sastre A, Govorkova EA, Guan Y, Herfst S, Kawaoka Y, Orenstein WA, Peiris JS, Perez DR, Richt JA, Russell C, Schultz-Cherry SL, Smith DJ, Steel J, Tompkins SM, Topham DJ, Treanor JJ, Tripp RA, Webby RJ, Webster RG.

Nature. 2013 Aug 8;500(7461):150-1. doi: 10.1038/500150a. No abstract available.

PMID:
23925229
35.

A novel influenza virus hemagglutinin-respiratory syncytial virus (RSV) fusion protein subunit vaccine against influenza and RSV.

Turner TM, Jones LP, Tompkins SM, Tripp RA.

J Virol. 2013 Oct;87(19):10792-804. doi: 10.1128/JVI.01724-13. Epub 2013 Jul 31.

36.

Antiviral responses by Swine primary bronchoepithelial cells are limited compared to human bronchoepithelial cells following influenza virus infection.

Hauser MJ, Dlugolenski D, Culhane MR, Wentworth DE, Tompkins SM, Tripp RA.

PLoS One. 2013 Jul 10;8(7):e70251. doi: 10.1371/journal.pone.0070251. Print 2013.

37.

Identification of Host Kinase Genes Required for Influenza Virus Replication and the Regulatory Role of MicroRNAs.

Bakre A, Andersen LE, Meliopoulos V, Coleman K, Yan X, Brooks P, Crabtree J, Tompkins SM, Tripp RA.

PLoS One. 2013 Jun 21;8(6):e66796. doi: 10.1371/journal.pone.0066796. Print 2013.

38.

Efficacy of parainfluenza virus 5 mutants expressing hemagglutinin from H5N1 influenza A virus in mice.

Li Z, Gabbard JD, Mooney A, Chen Z, Tompkins SM, He B.

J Virol. 2013 Sep;87(17):9604-9. doi: 10.1128/JVI.01289-13. Epub 2013 Jun 26.

39.

Induction and role of indoleamine 2,3 dioxygenase in mouse models of influenza a virus infection.

Huang L, Li L, Klonowski KD, Tompkins SM, Tripp RA, Mellor AL.

PLoS One. 2013 Jun 13;8(6):e66546. doi: 10.1371/journal.pone.0066546. Print 2013.

40.

Bat cells from Pteropus alecto are susceptible to influenza A virus infection and reassortment.

Dlugolenski D, Jones L, Tompkins SM, Crameri G, Wang LF, Tripp RA.

Influenza Other Respir Viruses. 2013 Nov;7(6):900-3. doi: 10.1111/irv.12128. Epub 2013 May 27.

41.

Potential directions for chicken immunology research.

Stewart CR, Keyburn AL, Deffrasnes C, Tompkins SM.

Dev Comp Immunol. 2013 Nov;41(3):463-8. doi: 10.1016/j.dci.2013.05.011. Epub 2013 May 21. Review.

PMID:
23707787
42.

Inhibition of indoleamine 2,3-dioxygenase enhances the T-cell response to influenza virus infection.

Fox JM, Sage LK, Huang L, Barber J, Klonowski KD, Mellor AL, Tompkins SM, Tripp RA.

J Gen Virol. 2013 Jul;94(Pt 7):1451-61. doi: 10.1099/vir.0.053124-0. Epub 2013 Apr 11.

43.

Subsisting H1N1 influenza memory responses are insufficient to protect from pandemic H1N1 influenza challenge in C57BL/6 mice.

Sage LK, Fox JM, Tompkins SM, Tripp RA.

J Gen Virol. 2013 Aug;94(Pt 8):1701-11. doi: 10.1099/vir.0.049494-0. Epub 2013 Apr 11.

44.

Experimental infection of European starlings (Sturnus vulgaris) and house sparrows (Passer domesticus) with pandemic 2009 H1N1 and swine H1N1 and H3N2 triple reassortant influenza viruses.

Nemeth NM, Oesterle PT, Poulson RL, Jones CA, Tompkins SM, Brown JD, Stallknecht DE.

J Wildl Dis. 2013 Apr;49(2):437-40. doi: 10.7589/2012-09-224.

PMID:
23568924
45.

Single-dose vaccination of a recombinant parainfluenza virus 5 expressing NP from H5N1 virus provides broad immunity against influenza A viruses.

Li Z, Gabbard JD, Mooney A, Gao X, Chen Z, Place RJ, Tompkins SM, He B.

J Virol. 2013 May;87(10):5985-93. doi: 10.1128/JVI.00120-13. Epub 2013 Mar 20.

46.
47.

Adenovirus 36, adiposity, and bone strength in late-adolescent females.

Laing EM, Tripp RA, Pollock NK, Baile CA, Della-Fera MA, Rayalam S, Tompkins SM, Keys DA, Lewis RD.

J Bone Miner Res. 2013 Mar;28(3):489-96. doi: 10.1002/jbmr.1776.

48.

Targeting organic anion transporter 3 with probenecid as a novel anti-influenza a virus strategy.

Perwitasari O, Yan X, Johnson S, White C, Brooks P, Tompkins SM, Tripp RA.

Antimicrob Agents Chemother. 2013 Jan;57(1):475-83. doi: 10.1128/AAC.01532-12. Epub 2012 Nov 5.

50.

Recombinant parainfluenza virus 5 expressing hemagglutinin of influenza A virus H5N1 protected mice against lethal highly pathogenic avian influenza virus H5N1 challenge.

Li Z, Mooney AJ, Gabbard JD, Gao X, Xu P, Place RJ, Hogan RJ, Tompkins SM, He B.

J Virol. 2013 Jan;87(1):354-62. doi: 10.1128/JVI.02321-12. Epub 2012 Oct 17.

Supplemental Content

Loading ...
Support Center